Clinical trials: Neuroepithelial Tumor
Recurrent GBM
A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma
Cerebraca Wafer (75 mg [(Z)-n-butylidenephthalide]) is designed for surgical combination to treat glioblastoma (GBM) diseases. High-grade glioma includes GBM (Grade IV, isocitrate dehydrogenase 1 [IDH1] wild-type) and anaplastic…
- Trial name
- NCT03234595
- Testing
- Cerebraca wafer
- Where
- 3 sites in Taiwan
- Volunteers
- 22 people
- Sponsor
- Everfront Biotech Co., Ltd.
Advanced Solid Tumors Cancer
A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)
This is an open-label, Phase 1, dose-escalation study to determine the maximum tolerated dose (MTD) and the recommended phase two dose (RPTD), and to assess the safety, preliminary efficacy, and pharmacokinetic (PK) profile of…
- Trial name
- NCT03234712
- Testing
- ABBV-321
- Where
- 18 sites in United States, Australia and 1 more
- Volunteers
- 62 people
- Sponsor
- AbbVie
Isocitrate Dehydrogenase Gene Mutation
A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in advanced or metastatic solid tumors with IDH mutation.
- Trial name
- NCT04762602
- Testing
- HMPL-306
- Where
- 11 sites in United States, Spain
- Volunteers
- 42 people
- Sponsor
- Hutchmed
Oligodendroglioma, Astrocytoma
First in Patient Study for PF-06840003 in Malignant Gliomas
This study will evaluate the safety and tolerability of increasing doses of PF-06840003 in patients with malignant gliomas.
- Conditions
- Oligodendroglioma, Astrocytoma, Malignant Glioma
- Trial name
- NCT02764151
- Testing
- PF-06840003
- Where
- 14 sites in United States
- Volunteers
- 17 people
- Sponsor
- Pfizer
Malignant Glioma
Post-Marketing Surveillance of Gliadel 7.7mg Implant (All-case Observational Study)
Post-marketing surveillance to investigate the clinical safety and effectiveness in patients of all implantation of Gliadel with malignant glioma in the actual medical setting.
- Trial name
- NCT02300532
- Testing
- No intervention
- Where
- 2 sites in Japan
- Volunteers
- 561 people
- Sponsor
- Eisai Co., Ltd.
Recurrent Malignant Glioma, Brain Glioblastoma
Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma
This is a phase II open-label study investigating the efficacy, safety and pharmacokinetic(PK) properties of OKN-007 combined with temozolomide(TMZ) in patients with recurrent glioblastoma(GBM).
- Trial name
- NCT04388475
- Testing
- OKN-007, Temozolomide (TMZ)
- Where
- 13 sites in United States
- Volunteers
- 57 people
- Sponsor
- Oblato, Inc.
Glioblastoma Multiforme
Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme.
Investigation on safety, tolerability and efficacy of H-1 parvovirus (H-1PV) in subjects suffering from glioblastoma multiforme.
- Trial name
- ParvOryx01 (NCT01301430)
- Testing
- H-1PV
- Where
- Germany
- Volunteers
- 18 people
- Sponsor
- Oryx GmbH & Co. KG
Recurrent Glioblastoma, High-Grade Glioma (WHO III-IV)
Evaluate the Safety and Preliminary Efficacy of the Combination of NaviFUS System With Re-irradiation for rGBM Patients
This is an open label, single arm, prospective, and pilot study. Eligible patients will be enrolled after acquiring the signed informed consent and then will receive the treatment of re-RT combined with FUS (FUS + re-RT) on an…
- Conditions
- Recurrent Glioblastoma, High-Grade Glioma (WHO III-IV), Brain Tumor Recurrent, Brain Tumor Adult
- Trial name
- NCT04988750
- Testing
- NaviFUS System
- Where
- Taiwan
- Volunteers
- 7 people
- Sponsor
- NaviFUS Corporation
Recurrent Glioblastoma
TTAC-0001 and Pembrolizumab Combination phase1b Trial in Recurrent Glioblastoma
This is a phase 1b, open-Label clinical trial to determine the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) of TTAC-0001 administered in combination with pembrolizumab in patients with…
- Trial name
- NCT03722342
- Testing
- TTAC-0001 and pembrolizumab combination
- Where
- 2 sites in Australia
- Volunteers
- 9 people
- Sponsor
- PharmAbcine
Recurrent or Progressive Malignant Glioma
A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma
This is a phase 1, multi-centre, sequential cohort, open-label, dose-escalation study of the safety, tolerability, and PK of ANG1005 in patients with recurrent or progressive malignant glioma.
- Trial name
- NCT00539344
- Testing
- ANG1005
- Where
- 6 sites in United States
- Volunteers
- 63 people
- Sponsor
- Angiochem Inc
Glioblastoma, Astrocytoma, Grade IV
Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection
The purpose of this study is to measure what effect the study drug XL765 (SAR245409) or the study drug XL147 (SAR245408) has on tumor tissue in subjects with recurrent glioblastoma (GB) who are candidates for surgical resection.
- Trial name
- NCT01240460
- Testing
- XL765 (SAR245409), XL147 (SAR245408)
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Sanofi
Solid Tumors (Phase 1), Relapsed/Recurrent GBM (Phase 2)
Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)
This is a multicenter, open-label, Phase 1/2, dose-escalation and dose expansion study of a CXCR4 inhibitor, USL311, alone and in combination with lomustine in subjects with advanced solid tumors (Phase 1) and subjects with…
- Trial name
- NCT02765165
- Testing
- USL311, Lomustine
- Where
- 6 sites in United States, Spain
- Volunteers
- 26 people
- Sponsor
- Proximagen, LLC
Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
Expanded Access to ANG1005 for Individual Patients
This is an expanded access study with ANG1005 treatment for two individual patients from Protocol ANG1005-CLN-03 with WHO Grade III Anaplastic Astrocytoma and WHO Grade III Anaplastic Oligodendroglioma and one individual patient…
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Breast Cancer With Recurrent Brain Metastases, Leptomeningeal Carcinomatosis
- Trial name
- NCT02755987
- Testing
- ANG1005
- Where
- 2 sites in United States
- Sponsor
- Angiochem Inc
Osteosarcoma, Neuroblastoma
Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor
Cd276 (B7-H3) is an ideal target for car-t treatment because of its high expression on the surface of neuroblastoma, osteosarcoma, gastric cancer and lung cancer cells, but not in normal peripheral cells or tissues.
- Conditions
- Osteosarcoma, Neuroblastoma, Gastric Cancer, Lung Cancer
- Trial name
- NCT04864821
- Testing
- Targeting CD276 CAR T cells
- Volunteers
- 24 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Glioma, Metastatic Brain Cancer
ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Brain Tumors
A Study to Evaluate the Safety and Feasibility of Transcranial MRI-Guided Focused Ultrasound Surgery in the Treatment of Brain Tumors
- Trial name
- NCT01473485
- Testing
- ExAblate Transcranial System
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- InSightec
Grade 2 IDH1-mutant Glioma, Grade 3 IDH1-mutant Glioma
Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
This study will include up to 40 participants with Grade 2 or Grade 3 IDH1-mutant glioma who have undergone surgery and received vorasidenib as their only treatment, experienced radiographic disease progression on vorasidenib…
- Conditions
- Grade 2 IDH1-mutant Glioma, Grade 3 IDH1-mutant Glioma, Glioma, IDH1-mutant Glioma
- Trial name
- NCT07703436
- Testing
- Safusidenib
- Where
- 12 sites in United States
- Volunteers
- 40 people
- Sponsor
- Nuvation Bio Inc.
Retinoblastoma
Retinoblastoma Phase II Expanded Access Clinical Trial
In this research study investigators want to learn more about treatment of advanced or recurrent retinoblastoma. For children with retinoblastoma that have an advanced stage of presentation in one eye or if they have failed all…
- Trial name
- NCT06679634
- Testing
- Chemoplaque also referred to as Episcleral Topotecan
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Targeted Therapy Technologies, LLC
Mixed Gliomas, Malignant Gliomas
A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas
The purpose of this study is to determine the safety and tolerability of XL765 in combination with Temozolomide in adults with anaplastic gliomas or glioblastoma on a stable Temozolomide maintenance dose.
- Conditions
- Mixed Gliomas, Malignant Gliomas, Glioblastoma Multiforme
- Trial name
- NCT00704080
- Testing
- XL765 (SAR245409), Temozolomide
- Where
- 6 sites in United States
- Volunteers
- 54 people
- Sponsor
- Sanofi
Multiple Myeloma, Diffuse Large B-Cell Lymphoma
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
The main purpose of this first human study with CC-223 is to assess the safety and action of a new class of experimental drug (dual mTOR inhibitors) in patients with advanced tumors unresponsive to standard therapies and to…
- Conditions
- Multiple Myeloma, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme, Hepatocellular Carcinoma
- Trial name
- NCT01177397
- Testing
- CC-223
- Where
- 16 sites in United States, France and 2 more
- Volunteers
- 226 people
- Sponsor
- Celgene
Glioblastoma Multiforme (GBM)
JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)
This study was designed to evaluate the safety, tolerability, efficacy and pharmacokinetics of JK-1201I combined with adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme after surgery and concomitant…
- Trial name
- NCT06595186
- Testing
- JK-1201I, Temozolomide (TMZ)
- Where
- China
- Volunteers
- 25 people
- Sponsor
- JenKem Technology Co., Ltd.